# GMMG-HD11/DSMM XXI/64007957MMY3010

> **NCT07671287** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Heidelberg Medical Center** · enrollment: 399 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Teclistamab
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib (B)
- **DRUG:** dexamethsone

## Key facts

- **NCT ID:** NCT07671287
- **Lead sponsor:** University of Heidelberg Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2031-02-14
- **Final completion:** 2033-01-30
- **Target enrollment:** 399 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671287, "GMMG-HD11/DSMM XXI/64007957MMY3010". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*